Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.

  • Etude concernée: IFCT-1601
  • Auteurs / Authors: Diane Damotte; Yoan Velut; Barbara Burroni; Gary Birsen; Julien Lavergne; Audrey Mansuet-Lupo; Isabelle Cremer; Julien Mazieres; Jacques Cadranel; Gerard Zalcman; Radj Gervais; Gaelle Jeannin; Olivier Molinier; Thomas Egenod; Olivier Carre; Celia Berndt; Alexandra Langlais; Franck Morin; Virginie Westeel; Marie Wislez
  • Journal / Conference: ASCO
  • Année / Year: 2024
  • PMID: Poster session
  • Lien vers la publication: images/IFCT-1601_poster-bio_Final_HighResolution.pdf
  • PDF: IFCT-1601_poster-bio_Final_HighResolution.pdf